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Introduction:
Ascertaining tumor drug resistance would allow clinicians to better individualize cancer therapy. Current practice utilizes factors such as age, tumor size, and pathological grade to determine the appropriate chemotherapeutic regimen. However, patients presenting with similar profiles do not always respond similarly to treatment (1) . It is estimated that as few as 50% of patients are responsive to current chemotherapeutic regimens (2) . Therefore, new methods of predicting tumor response to chemotherapy could enhance patient outcomes.
Differential expression microarrays to profile transcriptional variation between cancers have shown promise in predicting patient outcome to chemotherapeutic treatments (3, 4, 5, 6) . However, these approaches do not account for post-translational modifications and alternate splicing events inherent in the proteome. While the genome is estimated at roughly 23,000-40,000 genes (7, 8 ) the human proteome is thought to contain over 1 million proteins (9) . Thus, the greater complexity of the proteome provides opportunities to develop tumor profiles based on novel differences between cancer subtypes that differ in resistance to chemotherapy. Thus far, proteomic profiling has not been fully exploited to address this goal. To begin to access this complexity, we have developed surface proteome signature technology (SPS) as a complementary tool to current proteomic-profiling techniques such as 2D gel electrophoresis and mass 
Results:
Generation of scFv library development and test of SPS
SPS is based on comparative immunocytochemistry between two cell samples using an antibody library that assesses quantitative differences of surface expression between these samples. Our analysis focused on the surface proteome as a subset of the total proteome that, by virtue of accessibility, is potentially more amenable to drug discovery and therapeutic intervention. We previously developed a 700-component E-tag labeled single chain variable fragment (scFv) phage display library that recognizes surface antigens of HT1080 fibrosarcoma cells (10, 12) . By binding cells with an Etagged scFv followed by anti-E-tag mouse IgG, Alexa scFv 5d11, was knocked down in HT1080 cells and confirmed via western blot and immunofluorescent microscopy ( Figure 1A & B) . We compared the relative binding for a 10-scFv SPS, including 5d11, for both anti-PVR siRNA-treated HT1080 cells and HT1080 cells treated with a scrambled control ( Figure 1C) . SPS profiling revealed a marked difference (t-test, p=0.00008) of 5d11 fluorescence in anti-PVR siRNA treated HT1080 cells when compared to scramble siRNA control. In contrast, there was no significant difference observed in binding for the other surface antigens in the subset of scFvs employed. These findings indicated that SPS could detect specific differences in surface expression of HT1080 cells and served as a proof of principle for use of this technology.
We then tested for the sensitivity and reproducibility of our assay by comparing the SPS of two identical samples of MCF7 performed on separate days using a 70 scFv panel (~10% of our library). We defined potential biomarkers that distinguished between these cell lines by the following criteria: 1) having a greater than two-fold difference in binding between cell lines; 2) statistically significant difference in binding between cell lines as measured by t-test (P<0.01) and 3) a surface expression difference that repeats in a duplicate SPS screen. The vast majority of scFvs showed no significant difference in binding between samples (Figure 2A ). Three scFvs did show a significant difference in scFv surface binding but did not repeat in a secondary screen, and thus did not meet our established criteria. This experiment shows a false positive rate of ~ 4% (3 out of 70) inherent in any single SPS experiment but a repeat analysis can be used to rule out these false positives. Figure 2B ). We expected that SPS comparing cells of distinct lineage would be markedly different in their surface proteome and about 10% of the scFvs applied showed reproducible and significant differences. While there are numerous similarities in SPS between these two cell lines, we focused primarily on differences in surface binding as these represent candidates for potentially distinguishing biomarkers.
We tested the ability of scFvs identified by SPS to distinguish between HT1080 and MCF7 cell lines. We selected 2a8 and 2f8 (two scFvs that showed the largest difference in SPS) for use in fluorescent immunocytochemistry of samples of MCF7 and HT1080 cells and provided the resulting fluorescence signals to an observer blinded to the identity of the cell samples. 10 samples per cell line were assayed on three separate days to determine if day-to-day experimental variation affects scFv binding levels. Each individual sample consists of three wells containing 20,000 cells per well for a total of 30 samples. The average of these samples was used by the scorer to correctly identify 100% of the 60 total samples as being of either MCF7 or HT1080 based on the relative binding of 2a8 and 2f8. Figure 2C shows the average binding of single chain markers (±sem) for this experiment and clearly shows the difference in fluorescence signal for these scFvs between HT1080 and MCF7 cell samples. These findings indicate that scFvs identified by SPS can distinguish between these cell lines.
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SPS identifies CD44 as a biomarker that distinguishes MCF7 from NCI/ADR-RES cells
We next applied SPS to two cell lines of differing drug resistance: MCF7 vs.
NCI/ADR-RES, previously shown to have high expression of the drug efflux pump, pglycoprotein (MDR1) (13, 14, 15) . NCI/ADR-RES, formerly MCF7-Adr, was originally isolated from MCF7 by growth in gradually increasing concentrations of doxorubicin (16) and was thought to be a drug resistant subline. Recent analysis has suggested the NCI/ADR-RES cell line is actually an OVAR-8 contaminant of the original MCF7 population (17, 18) . In an Affymetrix microarray analysis of the NCI-60 cell line panel, there was a 98.7% similarity in SNP's between NCI/ADR-RES and the OVAR-8 ovarian carcinoma (19) . In addition, subsequent spectral karyotyping analysis performed on these cell lines showed a significant similarity between NCI/ADR-RES and the OVAR-8 cell line (19) . While the genomic analysis shows that NCI/ADR-RES are not derived from Due to this finding, we applied a 70-scFv SPS panel to these two cell lines to assess surface proteomic differences between MCF7 and NCI/ADR-RES in order to resolve this issue. As a positive control, we included an antibody against MDR1/pgp.
The overall goal was two-fold: to identify potential biomarkers useful in identifying cells that would be refractory to treatment with the chemotherapeutic doxorubicin and determine if MCF7 and NCI/ADR-RES express proteomically distinct profiles. SPS comparison of these two cell lines revealed two repeatable differences: MDR1/pgp 8 (positive control) and 4a1 ( Figure 3A ). These findings show that MCF7 and NCI/RES-ADR have very similar surface proteomes and that 4a1 recognizes a potential biomarker for drug resistance in NCI/ADR-RES cells. We performed IP/MS to identify the antigen bound by 4a1 (12) and established its identity as CD44, the hyaluronan receptor.
We tested if CD44 immunocytochemistry alone was sufficient to distinguish between MCF7 and the drug resistant line NCI/ADR-RES in a similar experiment as 
CD44 serves as a distinguishing biomarker in vivo
Our results show that CD44 expression can distinguish between NCI/ADR-RES and MCF7, two cell lines that differ in drug resistance in vitro, yet it was not clear if this, we generated MCF7 and NCI/ADR-RES tumors in a xenograft mouse model and performed CD44 immunohistochemistry on paraffin sections derived from these tumors.
In addition, we also addressed the ability of CD44 to predict tumor susceptibility to the chemotherapeutic drug doxorubicin. We transfected both cell lines with the firefly luciferase reporter construct pGL4. 13 for CD44 on both the cell surface and cytoplasm ( Figure 4B ). In the untreated control group, stained sections were assessed on a -/+ to +++ scale in a blinded fashion by an examiner who correctly identified 12 out of 12 tumors as being of MCF7 or NCI/ADR-RES (100%) ( Figure 4C ). These findings suggest that CD44 expression does not change significantly when these cells proliferate in vivo and that CD44 surface expression is a reliable distinguishing biomarker for tumors derived from these cell lines.
When we examined the doxorubicin-treated cohort (n=15), a blinded examiner used CD44 staining to correctly identified 86% of the NCI/ADR-RES and 75 % of the MCF7 tumors ( Figure 4D ). We also used this cohort to ask if CD44 can serve as a good predictor of tumor response to drug. Using the CD44 IHC as if it were a biopsy, a blinded examiner was asked to state whether this tumor would respond to doxorubicin 
MDR1/pgp
We sought to determine whether CD44 has a functional role in drug resistance.
While NCI/ADR-RES cells are thought to be drug resistant due to increased MDR1 expression (13, 14) , other proteins may also contribute. To test if CD44 affects doxorubicin sensitivity, we used siRNA to knock down expression of CD44, MDR1 or both in NCI/ADR-RES cells and tested for viability in doxorubicin ( Figure 5A ). As expected, loss of expression of MDR1 by siRNA decreased this resistance significantly when compared to control (IC 50 =18 ug/ml ± 3, P=. 0014; Figure 5A ). However, siRNA knockdown of CD44 also increased sensitivity to doxorubicin by 36%, (IC 50 =36 ug/ml ±4, P=. 0011) indicating a role for CD44 in the observed resistance to doxorubicin.
Moreover, when both MDR1 and CD44 expression were decreased via siRNA, the effects were additive, increasing NCI/ADR-RES cells susceptibility to doxorubicin by 95% (IC 50 = 5 ug/ml±0.5, P=.0001). These findings indicated that CD44 plays a role in doxorubicin drug resistance independent of MDR1. We tested this notion by assessing the effects of siRNA treatments on drug efflux, by measuring MDR1 transport of 3,3 diethyloxacarbocyanine iodide dye in cells treated with siRNA against MDR1 or CD44.
Loss of MDR1/pgp expression results in a marked decrease (31%) in dye efflux of when compared to control, whereas loss of CD44 had no observable effect on efflux ( Figure   5B ). The lack of dye efflux inhibition by CD44 siRNA knockdown supports a role for CD44 in drug resistance of NCI/ADR-RES cells by a mechanism independent of MDR/pgp mediated drug efflux. Together, these findings support the hypothesis that CD44 acts in NCI/ADR-RES drug resistance via a hyaluronan binding leading to increased Bcl-xL production consistent with its role in MCF7 cells (23) . These findings demonstrate the ability of SPS to identify CD44 as an additional and functional biomarker for drug resistance in both NCI/ADR-RES cells and tumors derived from these cells.
Discussion:
Development of diagnostic tools that can accurately predict tumor response to drug would be highly useful in the clinical setting. For example, clinical diagnostic kits using FISH or CISH to measure gene amplification have already been developed to identify herceptin-responsive patients (25) . Proteomic profiling has the potential to provide complementary and potentially more sensitive classification schemes for clinical tumors than those currently achieved by genomic methods. In this study, we developed SPS to begin to interrogate the surface proteome for distinguishing biomarkers. SPS 
potential biomarker for doxorubicin resistance that is highly expressed on NCI/ADR-RES cells compared to MCF7 cells. In addition, CD44 exhibited a diagnostic capability by predicting therapeutic outcome in MCF7 and NCI/ADR-RES xenograft tumors treated with doxorubicin. Furthermore, we demonstrated that CD44 acts in doxorubicin resistance independent of MDR1 and increases expression of Bcl-xL, an anti-apoptotic protein.
CD44 is ubiquitously expressed in human tissues and possesses multiple ligands such as hyaluronan, osteopontin, collagen and matrix metalloproteases (26,27,28). In addition, CD44 has been shown to be involved in numerous cellular processes such as lymphocyte activation and homing, hematopoiesis, and tumor metastasis (28) . However, its role in drug resistance remains unclear. One established mechanism for CD44 mediated drug resistance is via upregulation of MDR1 in response to challenge with hyaluronan (29) . Our findings indicate that CD44 also mediates drug resistance through a mechanism separate from MDR1. We tested two potential mechanisms for CD44 drug resistance and our findings support the notion that it functions as an anti-apoptotic factor through upregulation of Bcl-xL. Bcl-xL is an antiapoptotic protein thought to counteract pro-apoptotic mitochondrial swelling by maintaining mitochondrial membrane potential through its inherent ion channel activity Thus, CD44 inhibition of both the intrinsic and extrinsic pathways of apoptosis, may have a more profound effect on cancer cell survival.
Aggressive cancer cells secrete high levels of hyaluronan (33, 34, 35, 36 ) and hyaluronan synthases have been shown to be upregulated in cancer (37, 38) . We speculate that NCI/ADR-RES derived tumors are aggressive because they highly express CD44, leading to increased expression of Bcl-xL contributing to their drug and apoptotic resistance. Thus, we envision a feedback loop in which tumors possessing elevated CD44 levels and secreting high levels of hyaluronan would increase Bcl-xL expression, thereby enabling the cells to resist apoptosis, contributing to overall tumor survival. 
